Sobrevida de pacientes con cáncer de mama Her2 positivo tratadas en el Hospital de Solca Loja

Breast cancer HER2 positive (BRCA HER2 +) represents 20 to 30% of breast cancers, until before biological therapies was the most aggressive, with a 5-year survival of 74%. This is why arises the need for the current research whose main objective was to determine the 5-year survival in patients with...

• Κύριος συγγραφέας: Macas Cabrera, Brayan Edison (author)
• Μορφή: bachelorThesis
• Γλώσσα: spa
• Έκδοση: 2019
• Θέματα: CÁNCER MAMA; CÁNCER - MAMA HER2
• Διαθέσιμο Online: http://dspace.unl.edu.ec/jspui/handle/123456789/22031